Alnylam Pharmaceuticals Inc. is experiencing a notable rise in stock value as it advances its innovative therapies aimed at Alzheimer's disease.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is up 1.63% today, closing at CA$250.53. The company's recent developments in Alzheimer's drug therapies have caught investors' attention, reflecting optimism in its clinical pipeline.
Investor takeaway: Investors are encouraged by Alnylam's advancements in RNA interference therapies, especially in addressing Alzheimer's disease, which could enhance its market position and drive future growth.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$33.67B
P/E
42.6x
52W high
$495.55
52W low
$197.81
1W change
+2.99%
Beta
0.30
Analyst Price Targets
Based on 30 analysts covering ALNY · as of Sep 17, 2026
Wall Street analysts forecast ALNY stock price to rise 50.6% over the next 12 months.
Consensus
Buy4.23 / 5.00
Avg. Target
C$371.35
+50.6% Upside
Current Price
C$246.51
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
45.7%
Annualized
90-Day Vol
78.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$206.20
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$232.26 | C$198.38 – C$271.94 |
| 60 trading days | C$218.84 | C$175.10 – C$273.52 |
| 90 trading days | C$206.20 | C$156.91 – C$270.96 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Alnylam's Market Cap Reaches CA$32.99 Billion
With a market capitalization of CA$32.99 billion, Alnylam is well-positioned to continue investing in research and development, particularly in the lucrative field of RNA interference therapies.
Bull case
Alnylam's innovative approach to treating Alzheimer's disease with mivelsiran shows promising results in early trials. This could position the company as a leader in the growing market for neurodegenerative therapies.
Bear case
Despite today's gains, Alnylam faces stiff competition in the Alzheimer's space and the inherent risks of drug development, which could affect its long-term performance.
Advertisement
Alnylam's Breakthrough in Alzheimer's Research
Alnylam Pharmaceuticals is advancing its experimental RNAi therapy, mivelsiran, which aims to reduce amyloid precursor protein (APP) levels in the brain. Recent phase I data revealed encouraging results, prompting the company to move forward with a phase II study targeting patients with Down syndrome-associated Alzheimer's disease. This innovative approach could significantly impact the treatment landscape for Alzheimer's, a condition that affects millions worldwide.
Market Dynamics and Future Prospects
The global RNA interference therapeutics market is projected to reach USD 31.4 billion by 2035, driven by advancements in genetic research and the increasing prevalence of rare diseases. Alnylam, with its strong pipeline and focus on RNAi therapies, is strategically positioned to capitalize on this growth. Investors are closely watching the company's progress as it navigates the complexities of drug development in a competitive environment.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
